Loading this company
Hims & Hers Health, Inc.
HIMSPrices in USD
TickerWorth ScoreC33–61 of 100
What we think
We do not publish a fair value for this company. The grade still applies.
Price
$28.43USD up +$0.36 (+1.28%)
Close of · Prices are delayed.
Why did it move today?
Nothing we can cite explains today’s move for this company.
We do not put a fair value on this one
Our cash-flow model doesn't produce a meaningful value for this business — its projected free cash flow is so far from supporting the current price that the result is effectively zero, which tells you about the limits of the model on a fast-growing or loss-making company, not about what the business is worth. Here is what we can show instead.
Is it a good business?
- Valuation0 out of 100
- Growth100 out of 100
- Financial health17 out of 100
- Past performance0 out of 100
Bull, base, bear
Our forward range over 12 months is part of Pro. See plans
The street
Analysts’ mean target
$31.15 across 13 analysts
The high and low of the analyst range is part of Pro. See plans
What does it do?
Hims & Hers Health, Inc. operates as a consumer-first health and wellness platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, Canada, Germany, the Republic of Ireland, France, Spain, Australia, and internationally. It operates in the Drug Manufacturers - Specialty & Generic industry (Healthcare sector), headquartered in United States. The company employs roughly 2,442 people.
Key stats
52-week range$13.74–$52.41
- Open
- $28.49
- Day high
- $29.00
- Day low
- $27.54
- Previous close
- $28.07
- Volume
- 3,187,842 · 0.26× avg
- Average volume
- 12,115,692
- Market cap
- $6,699,594,752.00
- P/E (TTM)
- —
- Earnings per share
- −$0.64
- Beta
- 2.43
Prices are delayed. The feed does not say when these figures were taken.
What’s the latest?
- Changed leadership or its board
- Reported quarterly or annual results
- Changed leadership or its board
- Signed a material agreement
- Reported shareholder vote results
- Signed a material agreement
- Signed a material agreement
Top news
No recent headlines we can cite for this company.
Insider trades
The 90-day buying-and-selling read is part of Pro. See plans
- Boughton SoleilOpen-market sale · $100,576.66
- Okupe OluyemiOpen-market sale ·
Not investment advice. TickerWorth Score is a model output.